Vincerx Pharma, Inc.
VINCHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$31.5M | −$42.6M | −$71.2M | −$62.7M | −$172,996 | −$1,450 |
| Net income | −$30.1M | −$40.2M | −$63.0M | −$39.3M | −$119,542 | −$1,450 |
| Total assets | $8.0M | $18.2M | $59.3M | $117.7M | $66.5M | $25,000 |
| Total liabilities | $5.3M | $7.0M | $11.6M | $17.4M | $3.4M | $1,450 |
| Equity | $2.7M | $11.2M | $47.7M | $100.3M | $5.0M | $23,550 |
| EPS (diluted) | $-15.85 | $-37.72 | $-3.00 | $-2.29 | — | — |
| Shares out. | 21.4M | 21.2M | 21.1M | 21.1M | 8.2M | 1.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −1104.0%
- Return on assets
- −375.7%
- Return on capital (ROCE)
- −1155.0%
- Liabilities / assets
- 66.0%
- Debt / equity
- 1.94×
- Book value / share
- $0.13
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -101.99distress
- Accruals / assets
- −49.3%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Sage Rhino Capital LlcPassive (13G)Jul 29, 2025
- Armistice Capital, LlcPassive (13G)May 15, 2025
- Prosight Management, LpPassive (13G)Feb 12, 2025
- Long Focus Capital Management, LlcPassive (13G)Feb 11, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 966 | 1.0 | 0.0% |
| Apr 30, 2026 | 966 | 1.0 | 0.0% |
| Apr 15, 2026 | 966 | 1.1 | -3.3% |
| Mar 31, 2026 | 999 | 1.0 | 0.0% |
| Mar 13, 2026 | 999 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Director / officer change · Other material eventJul 7, 2025
- Delisting / listing-standard notice · Other material eventApr 17, 2025
- Terminated a material agreement · Other material eventApr 11, 2025
- Entered a material agreement · Other material eventMar 18, 2025
- Terminated a material agreement · Other material eventFeb 28, 2025
- Other material eventFeb 18, 2025
- Entered a material agreementFeb 6, 2025
- Regulation FD disclosureJan 23, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.